Canton

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Head and neck cancer1 trial
• Multiple myeloma1 trial
• Myelodysplastic syndromes1 trial
• Ovarian cancer1 trial

Phase

• Phase 1/23 trials
• Phase 33 trials
• Phase 11 trial
• Phase 21 trial

Status

• Recruiting6 trials
• Active, not recruiting1 trial
• Completed1 trial

Lead sponsor

• GlaxoSmithKline6 trials
• Tesaro, Inc.2 trials

Running trials

• Recruiting

  A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

  NCT07602855· Phase 1/2· GlaxoSmithKline· Source

  Contact: Nashat Gabrail (principal investigator)

• Recruiting

  A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

  NCT07213609· Phase 1/2· GlaxoSmithKline· Source

  Contact: Nashat Gabrail (principal investigator)

• Recruiting

  A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  NCT07099898· Phase 3· GlaxoSmithKline· Source

  Contact: Nashat Gabrail (principal investigator)

• Recruiting

  A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

  NCT06847867· Phase 2· GlaxoSmithKline· Source

  Contact: Nashat Gabrail (principal investigator)

• Recruiting

  A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  NCT06256588· Phase 3· GlaxoSmithKline· Source

  Contact: Nashat Gabrail (principal investigator)

• Recruiting

  A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

  NCT05714839· Phase 1/2· GlaxoSmithKline· Source

  Contact: Nashat Gabrail (principal investigator)

• Active, not recruiting

  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

  NCT03602859· Phase 3· Tesaro, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting

Closed trials

• Completed

  Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

  NCT03307785· Phase 1· Tesaro, Inc.· Source